Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFAZOLIN AND DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFAZOLIN AND DEXTROSE.
CECLOR CD vs CEFAZOLIN AND DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic